The Genomics Facility (GF) was created by merging previously approved CCSG cores (Research Cytogenetics and Laser Capture Microdissection, DNA Microarray, and Cancer Prevention Biomarker and Genotyping Facilities) in order to increase cost-effectiveness and efficiency, consolidate space, increase intellectual and technical communication among staff, and provide cross-training important for laboratory stability. In addition, the Real-Time PCR service, previously part of the Biochemistry &Biotechnology Facility, was integrated into the merged GF to avoid redundancy. This merger was recommended by a Facility Parent Oversight Committee (FPOC). The FPOC is an institutional committee comprised of a Faculty Chair and mid to senior level faculty. The FPOC mandate is to prioritize CCSG funded shared resources. The GF consists of four component services: Cytogenetics &Chromosome Microarray Analysis, Laser Capture Microdissection (LCM), DNA Microarray, Genotyping and Real-time PCR. The Cytogenetics and Chromosome Microarray Analysis services performs classical cytogenetics and molecular cytogenetics, as well as high-resolution DNA copy number analysis for the detection of genomic imbalances, including chromosomal deletions and amplifications. The LCM service provides instrumentation and expertise needed for isolating pure cell populations from heterogeneous tissue specimens. The purified DNA, RNA or protein from captured cells can be used for a wide range of downstream applications such as gene expression analysis, DNA sequencing, and proteomic assays. The DNA Microarray service provides investigators with gene expression analysis solutions for cancer research. The services of this unit include microarray experimental design, RNA sample labeling, hybridization and scanning. The Genotyping and Real-time PCR service provides various platforms and expertise for genome-wide and targeted DNA and RNA analyses as well as quantitative real-time PCR services. Thirty-six peer-reviewed, funded investigators utilized the GF in CY2009. Merging the previously distinct cores has provided both operational and economic advantages. The institution has provided contiguous laboratory space for this merged operation to promote synergies such as cross training, sharing of equipment and efficiency of workflow. In addition, the merger has produced real cost savings. Unifying the operation has reduced by 1.7 the total FTE's dedicated to providing these services previously as separate cores.

Public Health Relevance

The GF addresses the genomic and gene expression needs of the Center's Pis, many of whom conduct research aimed at understanding the genetic and epigenetic underpinnings of tumor formation and progression. The Facility assists investigators to unravel biomarkers or molecular signatures of cancer that may improve patient care by affording advances in the earty detection, diagnosis and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475346
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$110,182
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Fahl, Shawn P; Coffey, Francis; Kain, Lisa et al. (2018) Role of a selecting ligand in shaping the murine ??-TCR repertoire. Proc Natl Acad Sci U S A 115:1889-1894
Jones, Caitlin E; Hammer, Anisha M; Cho, YouJin et al. (2018) Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland. Neoplasia 21:132-145
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961

Showing the most recent 10 out of 1280 publications